je.st
news
J&J says Jardiance survival benefit likely to be seen by Invokana
2015-10-13 17:50:49| Food - Topix.net
REUTERS: Johnson & Johnson said on Tuesday that the ability of Eli Lilly and Co's rival Jardiance diabetes drug to save lives in a large clinical trial is likely to benefit the entire class of drugs, including J&J's own approved Invokana treatment. Dominic Caruso, J&J's chief financial officer, gave his optimistic view of the new drug class, called SGLT2 inhibitors, on a conference call on Tuesday with industry analysts to discuss the company's third-quarter earnings.
Tags: to
seen
benefit
survival
Category:Food and Related Products